Novitas says Pacific Edge’s CxBladder tests are ‘not payable’

Novitas says Pacific Edge’s CxBladder tests are ‘not payable’
The company can continue to apply for renewed coverage. (Image: Pacific Edge)
Rebecca Howard
The long-awaited draft Local Coverage Determination from Novitas is not good news for Pacific Edge’s US business. According to the determination (LCD), “CxBladder tests are not reasonable and necessary to support positive outcomes in the management of bladder cancer and, therefore, are not payable”.In June 2023, Pacific Edge confirmed that the LCD from Novitas — its Medicare administrative contractor — meant its flagship Cxbladder test for bladder cancer didn’t meet the threshold required for coverage un...

More Markets

Gentrack leads NZ sharemarket down almost 1%
Markets Market Close

Gentrack leads NZ sharemarket down almost 1%

The S&P/NZX 50 Index closed at 12,225.28, down 113.29 points or 0.92%.

Takeovers Panel will meet on NZME issue
Markets

Takeovers Panel will meet on NZME issue

The panel said in a media release today it had met on the issue of Grenon’s shareholding.

Asian stocks extend global rout
Markets

Asian stocks extend global rout

Tokyo shares fall as Trump predicts a coming US boom.

AFP 4:45pm
KMD Brands pulled into Trump trade war
Retail

KMD Brands pulled into Trump trade war

Like a lot associated with so-called ‘Liberation Day’, much remains uncertain.